Journal of Neuromuscular Diseases Celebrates 10-Year Anniversary with Commemorative Editorial
The January 2024 edition of the Journal of Neuromuscular Diseases (JND) marked the journal’s 10-year anniversary! This is a special milestone for the publication that serves the international community as a publication for neuromuscular translational research, aiming to facilitate progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular disease.
In recognition of this occasion, Co-Editors-in-Chief of the JND, Dr. Hanns Lochmüller and Dr. Carsten Bonnëmann have published the editorial “The First Decade of Journal of Neuromuscular Diseases: Supporting and Advancing the Rapidly Evolving Field of Translational Research”, a review of the evolution of the JND from conception to current day.
Highlights from the editorial include:
- Remarks on the initial need for the journal
- Benchmarks of the journal’s impact and growth
- A content summary of JND publications by disease type, demographics, and research methodologies
- Discussion on recent trends, inspiration, and hope for the future of translational neuromuscular research
The entire team at the JND are proud to have been part of the past decade of exciting advancements in preclinical and clinical translational neuromuscular research, and look forward to another decade of growing the journal and serving the neuromuscular community.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.